Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Completed

• Conditions: Colorectal Cancer; Breast Cancer; Lung Cancer
• Interventions: Behavioral: Focus groups

• Registration Number: NCT02565017
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09-15
• Study First Submitted: 2015-09-30
• Study First Submitted QC: 2015-09-30
• Study First Posted: 2015-10-01
• Status Verified: 2019-08
• Primary Completion: 2020-06-22
• Study Completion: 2020-06-22
• Last Update Submitted: 2020-06-23
• Last Update Posted: 2020-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• MSKCC patient 18 years or older

• Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either:

  • Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK
  • OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK
  • OR chemotherapeutic treatment through an on-going MSK clinical trial as per clinician

• Residing in New York metro-area

Read More

Exclusion Criteria

• Non-English speakers because we do not have the resources to conduct and translate the focus groups into other languages
• Patients who are not or will not receive their cancer care at MSKCC.
• Patient unwilling or unable to provide informed consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Breast Cancer	Focus groups	and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
Lung Cancer	Focus groups	and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
Colorectal Cancer	Focus groups	and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).

Primary Outcome Measures

Name	Time	Method
Acceptability of IBM Watson Oncology	1 year	Data collected through the brief questionnaires (e.g.,initial impressions of IBM Watson Oncology, sociodemographics) will be entered into an SPSS data file on the secure MSK server.

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States